Myelodysplastic Syndrome — Research Summary
Printed from RareWays (rareways.com.au) on 26 July 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Poor sleep quality correlates with axial symptoms and mood problems in Parkinson's disease.
Taniguchi Seira et al. — Dialogues in clinical neuroscience (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/42290512/
- 2.
Rabdosin B suppresses proliferation of nonsmall cell lung cancer by regulating the SRC/PI3K/AKT signaling pathway.
Chen Xinfei et al. — Pharmaceutical biology (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41858068/
- 3.
Association between red cell distribution width to albumin ratio and all-cause mortality in critically ill patients with myelodysplastic syndrome: a retrospective cohort study.
Huang Zicong et al. — Hematology (Amsterdam, Netherlands) (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41841600/
- 4.
Engineered decellularized muscle extracellular matrix fabrics enable functional volumetric muscle loss repair.
Song Guangzhou et al. — Bioactive materials (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42306336/
- 5.
Clinical characteristics and predictors of disease progression in parkinson's disease in a cohort of patients in the ashanti region, Ghana.
Obese Vida et al. — Equity neuroscience (1 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42245155/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study to Evaluate the Safety and Tolerability of EP0042
Recruiting — Phase 1 — Ellipses Pharma
https://clinicaltrials.gov/study/NCT04581512
- 2.
A Study to Investigate APL-4098 Alone and in Combination in Adults With AML or MDS
Recruiting — Phase 1 — Apollo Therapeutics Ltd
https://clinicaltrials.gov/study/NCT06372717
- 3.
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
Recruiting — Phase 1 — Disc Medicine, Inc
https://clinicaltrials.gov/study/NCT05320198
- 4.
A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions
Recruiting — Phase 3 — Takeda
https://clinicaltrials.gov/study/NCT06499285
- 5.
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Recruiting — Phase 1 — PedAL BCU, LLC
https://clinicaltrials.gov/study/NCT04726241
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Myelodysplastic Syndrome
Myelodysplastic Syndrome encompasses a group of blood cancers in which the bone marrow produces abnormal, dysfunctional blood cells. The condition predominantly affects older adults and can progress to acute myeloid leukaemia. Treatment ranges from supportive care and growth factors to stem cell transplantation in eligible patients.
Most Recent Research
INTRODUCTION: Sleep disturbances and impaired bed mobility are common in Parkinson's disease (PD). We examined whether objectively measured sleep efficiency is associated with axial motor impairment and explored its potential relationship with cognitive and mood profiles. METHODS: Twenty-eight patients with PD underwent single-night EEG-based sleep monitoring and assessment of nocturnal turning. Partial correlations between sleep metrics and scores on motor, cognitive and mood outcomes were analysed, controlling for age, sex and the MDS-UPDRS 3. Family-wise error (FWE) correction was applied within each sleep predictor. RESULTS: Poor sleep efficiency correlated with higher MDS-UPDRS axial subscore (rpartial = -.615) and this association survived stringent correction for multiple comparisons (FWE-p = .018). However, its associations with PIGD and clinically rated freezing of gait did not remain significant after the correction. Exploratory analyses showed the relationships of N1 percentage with mood disturbances and REM latency with self-reported freezing of gait, of which only the relationship of N1 percentage with depression score showed a trend towards significance after the correction (rpartial =.551, FWE-p = .074). CONCLUSION: Poor objective sleep quality was robustly associated with axial motor severity in PD, independent of overall motor burden. Sleep efficiency may represent a clinically accessible marker of shared brainstem-related pathology underlying axial dysfunction.
Common Questions
What is Myelodysplastic Syndrome?
Myelodysplastic Syndrome encompasses a group of blood cancers in which the bone marrow produces abnormal, dysfunctional blood cells. The condition predominantly affects older adults and can progress to acute myeloid leukaemia. Treatment ranges from supportive care and growth factors to stem cell transplantation in eligible patients.
How many clinical trials are available for Myelodysplastic Syndrome?
RareWays currently indexes 1691 clinical trials for Myelodysplastic Syndrome, of which 323 are actively recruiting. Trial availability changes as new studies are registered — check the trials tab for current status.
Where does the research data for Myelodysplastic Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is updated regularly by Rocky, RareWays' automated research engine. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Myelodysplastic Syndrome.
No spam. Unsubscribe any time. Not medical advice.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.